

## Author Index

- A**  
Anderson, David J., 97
- B**  
Bhandari, Komal, 25  
Bonci, Antonello, 173  
Boyden, Edward, 239
- C**  
Caroni, Pico, 25  
Chowdhury, Ananya, 25  
Cui, Yihui, 141  
Cummings, Damian M., 151
- D**  
Dan, Yang, 243  
Delevich, Kristen, 37  
Ding, Keke, 97  
Dolmetsch, Ricardo E., 185,  
246  
Dong, Yiyang, 141
- E**  
Edwards, Frances A., 151
- F**  
Falcon, Benjamin, 163  
Frost Bellgowan, Julie A., 1
- G**  
Ghetti, Bernardino, 163  
Glimcher, Paul, 249
- Goedert, Michel, 163, 252  
Gordon, Joshua A., 1, 255  
Grant, Seth G.N., 45
- H**  
Hu, Hailan, 141
- I**  
Izquierdo, Pablo, 151
- J**  
Joel, Zelah, 151
- K**  
Kaur, Satvinder, 63  
Kepecs, Adam, 9, 219, 258  
Kishida, Kenneth T., 71  
Klawonn, Robert C., 119
- L**  
Lawhorn, Collene, 1  
Lee, Brian J., 17  
Lee, Darrin J., 201  
Leshan, Rebecca, 239, 243,  
249, 268, 287  
Lozano, Andres M., 201
- M**  
Madeo, Graziella, 173  
Malenka, Robert C., 119, 261  
Masset, Paul, 9  
Mayberg, Helen, 264  
McKnight, Steven L., 207
- Mews, Philipp, 131  
Montague, P. Read, 71, 229,  
268  
Mukherjee, Arghya, 25
- N**  
Namkung, Ho, 17  
Nestler, Eric J., 131
- O**  
Ott, Torben, 9
- P**  
Pieper, Andrew A., 207  
Platt, Michael, 272
- R**  
Richardson, Jill C., 151
- S**  
Saawa, Akira, 17  
Salih, Dervis A., 151  
Saper, Clifford B., 63  
Schaffer, Matthew, 105  
Scheinert, Rachel B., 1  
Scheres, Sjors H. W., 163  
Schiller, Daniela, 105, 275  
Sehgal, Amita, 57  
Shi, Mi, 57  
Small, Scott A., 193, 277  
Stevens, Beth, 280  
Stix, Gary, 246, 261, 284  
Sun, Yishan, 185
- Swanson, Larry W., 193
- T**  
Thomas, A. Wren, 37  
Thuault, Sébastien, 258, 264  
Toda, Hirofumi, 57  
Tripodi, Matteo, 25  
Tsai, Li-Huei, 284  
Tye, Kay, 287
- U**  
Uchida, Naoshigi, 83
- V**  
Vyas, Sejal, 277, 280, 290
- W**  
Walker, Deena M., 131  
Watabe-Uchida, Mitsuko, 83  
Wilbrecht, Linda, 37  
Williams, Julie A., 57  
Witkowski, Jan, 252, 255, 272,  
275, 293
- Y**  
Yang, Yan, 141  
Yanik, Mehmet Fatih, 290
- Z**  
Zelikowsky, Moriel, 97  
Zhang, Wenjuan, 163  
Zoghbi, Huda, 293

This is a free sample of content from Cold Spring Harbor Symposium on Quantitative Biology. Volume LXXXIII:  
Brains and Behavior: Order and Disorder in the Nervous System. [Click here](#) for more information on how to buy the book.

## Subject Index

### A

- AD. *See* Alzheimer's disease
- Addiction. *See* Substance abuse
- ADI. *See* Autism Diagnostic Interview
- AI. *See* Artificial intelligence
- AlphaGo, 233
- Altruism, 274
- Alzheimer's disease (AD)
  - APP expression modulation, 294–295
  - deep brain stimulation studies
    - fornix, 202–203
    - mechanism of action, 204
    - Papez circuit, 201–202
    - prospects, 204
    - striatum, 203–204
  - entorhinal–perirhinal borderzone vulnerability
    - connectivity pattern, 194–195
    - network hypothesis
      - anatomical spread, 197–198
      - regional vulnerability, 195–197
    - overview, 193–194, 277
    - prospects for study, 198
  - light therapy, 285–286
  - mouse models
    - APP overexpression, 152
    - behavioral deficits, 153
    - overexpression artifacts, 152–153
    - overview, 151–152
    - PSEN1/2 overexpression, 152
    - Tau overexpression
      - overview, 153–154
      - prospects, 158–159
      - toxicity threshold, 154, 156
  - structural studies, 252–253
  - tau conformers, 166–167
- Anxiety. *See* Social anxiety disorder
- Apnea. *See* Obstructive sleep apnea
- APOE4, 197
- APP. *See* Alzheimer's disease, 152
- Artificial intelligence (AI), 242, 268, 274, 292
- ASD. *See* Autism spectrum disorder
- Autism Diagnostic Interview (ADI), 235
- Autism spectrum disorder (ASD)
  - approaches to study, 247–248
  - hippocampal abnormalities, 109–110
  - social dysfunction, 109
  - social mapping impairment, 110
  - zebrafish model, 290

### B

- Biomarkers, discovery for psychiatric disease, 2

### BRAIN Initiative, 6

### C

- Calcitonin gene-related peptide (CGRP),
  - apnea arousal circuitry, 66
- Cannabidiol (CBD), effects in Dravet syndrome cell culture model, 185–190
- Categorical approach, brain disorder modeling, 18
- CBD. *See* Cannabidiol
- CD47, 281–282
- CGRP. *See* Calcitonin gene-related peptide
- Confidence
  - metacognition studies, 14–15
  - neural mechanisms, 13–14
  - neurons
    - classification, 13
    - identification, 12–13
  - overview, 9–10
  - statistical decision confidence
    - human studies, 12
    - theory, 10–11
- Confidence. *See* Decision confidence
- Corticotropin-releasing hormone (CRH),
  - social isolation stress role, 101
- CRH. *See* Corticotropin-releasing hormone

### D

- DBS. *See* Deep brain stimulation
- Decision confidence, 258–260
- Deep Blue, 229–230
- Deep brain stimulation (DBS)
  - Alzheimer's disease studies
    - fornix, 202–203
    - mechanism of action, 204
    - Papez circuit, 201–202
    - prospects, 204
    - striatum, 203–204
  - applications, 222, 264–267
  - depression studies, 264–267
  - Parkinson's disease, 264–267
- Depression. *See* Major depressive disorder
- Dimensional approach, brain disorder modeling, 18–19
- Dopamine. *See also* Electrochemical detection, neurotransmitters;
  - Nucleus accumbens;
  - Reward prediction error;
  - Striatum
- canonical signaling, 83–84
- measurement in brain, 233–234
- neuron diversity
  - activity, 85–88
  - connectivity, 84–85
  - function, 87–90
  - noncanonical signaling, 84
  - striatum compartmentalization based on dopamine signals, 91–93

- Dravet syndrome
  - cannabidiol effects in cell culture model
    - calcium assay, 190
    - cortical neuron culture, 189–190
    - electrophysiology, 190
    - findings, 186–189
    - induced pluripotent stem cell generation and differentiation, 190
  - overview, 185, 247
  - SCN1A mutations, 185
- Drop-seq, 280
- Drug abuse. *See* Substance abuse

### E

- Ecstasy
  - clinical applications, 263
  - serotonin transporter binding, 263
- EEG. *See* Electroencephalography
- Elastic net electrochemistry. *See*
  - Electrochemical detection, neurotransmitters
- Electrochemical detection,
  - neurotransmitters
- elastic net electrochemistry
  - multianalyte analysis, 75–76
  - principles, 72–75
  - striatum studies during active investment game, 76–79
- overview, 71–72
- reward prediction error hypothesis testing, 80–81
- Electroencephalography (EEG), sleep studies, 244
- Entorhinal–perirhinal borderzone. *See* Alzheimer's disease
- Epilepsy. *See also* Dravet syndrome
  - light-emitting diode therapy, 285
  - zebrafish model, 290
- EPSC. *See* Excitatory postsynaptic current
- Essential tremor, 269
- Excitatory postsynaptic current (EPSC), 49, 51

### F

- fMRI. *See* Functional magnetic resonance imaging
- Fornix, deep brain stimulation in Alzheimer's disease, 202–203

Functional magnetic resonance imaging (fMRI)  
decision-making studies, 250  
depression subtypes, 4  
social space studies, 275  
trust game, 234

**G**

GAD67, 26–27  
Galanin, nucleus accumbens actions, 125  
Gamma oscillations, modulation, 285–286  
Gaze, monkeys versus humans in game play, 274  
Genome-wide association study (GWAS)  
prospects, 2  
psychiatric disease mechanism identification, 17–18, 20  
GWAS. *See* Genome-wide association study

**H**

Habenula  
lateral habenula function, 141  
major depressive disorder studies  
bursting activity  
increase in animal models of depression, 143–144  
ionic mechanism, 144–146  
ketamine targeting, 144  
Kir4.1  
bidirectional modulation, 142–143  
bursting activity regulation, 146–148  
upregulation in astroglia, 142  
Hebb's rule, 232  
Hippocampus  
autism spectrum disorder abnormalities, 109–110  
functional overview, 105–106  
major depressive disorder abnormalities, 111  
schizophrenia abnormalities, 108–109  
social anxiety disorder abnormalities, 112  
social mapping neural mechanisms, 107  
social navigation, 107  
social space mapping, 106–107  
Hippocampus. *See also* Fornix

**K**

Ketamine, antidepressant actions in habenula, 144  
Kir4.1. *See* Habenula

**L**

LED. *See* Light-emitting diode  
Levetiracetam, 285  
Light-emitting diode (LED), therapy, 285–286

**M**

Major depressive disorder (MDD)

deep brain stimulation studies, 264–267  
habenula studies  
bursting activity  
increase in animal models of depression, 143–144  
ionic mechanism, 144–146  
ketamine targeting, 144  
Kir4.1  
bidirectional modulation, 142–143  
bursting activity regulation, 146–148  
upregulation in astroglia, 142  
hippocampal abnormalities, 111  
social dysfunction, 110–111  
social mapping impairment, 111

*MAPT*. *See* Tau  
MDD. *See* Major depressive disorder  
MDMA. *See* Ecstasy  
*MECP2*, 295  
Melanocortin, nucleus accumbens actions, 125

Mendelian randomization (MR), 20  
Microglia, 280–283  
MR. *See* Mendelian randomization  
MS. *See* Multiple sclerosis  
Multiple sclerosis (MS), 247  
Multivesicular body (MVB), fusion in Alzheimer's disease, 196  
MVB. *See* Multivesicular body

**N**

Nac. *See* Nucleus accumbens  
nAChR. *See* Nicotinic acetylcholine receptor  
NAD<sup>+</sup>. *See* Nicotinamide adenine dinucleotide  
*nemuri*  
antimicrobial peptide product, 59  
overexpression and sleep induction, 58–59  
sleep deprivation induction, 59–60  
Neuroeconomics, 249–250  
Nicotinamide adenine dinucleotide (NAD<sup>+</sup>)  
neuron protection overview, 207  
P7C3 effects, 211–212  
SARM1 as hydroxylase, 211  
Nicotinic acetylcholine receptor (nAChR),  
sleep mutants in  
*Drosophila*, 58  
Norepinephrine. *See* Electrochemical detection, neurotransmitters  
NTS. *See* Nucleus of the solitary tract  
Nucleus accumbens (NAc)  
dopamine actions, 121–123  
drug addiction  
gene expression long-lasting changes, 133–134  
medium spiny neurons, 137–138  
plasticity changes, 132–133  
excitatory inputs, 120–121  
expectation studies, 256  
medium spiny neurons expressing D1 and D2 receptors, 119–120, 256

neuropeptide modulation, 124–125  
serotonin actions, 123–124  
Nucleus of the solitary tract (NTS), apnea arousal circuitry, 63–64

**O**

Obsessive–compulsive disorder (OCD),  
deep brain stimulation, 266  
Obstructive sleep apnea (OSA)  
arousal circuitry, 63–69  
treatment, 63  
OCD. *See* Obsessive–compulsive disorder  
OFC. *See* Orbitofrontal cortex  
Opioid signaling, nucleus accumbens, 124–125  
Orbitofrontal cortex (OFC), decision confidence studies, 259  
Orexin, nucleus accumbens actions, 125  
OSA. *See* Obstructive sleep apnea  
Oxytocin, 125, 262

**P**

P7C3  
discovery, 211  
mechanism of neuroprotection, 211–212  
Papez circuit, deep brain stimulation in Alzheimer's disease, 201–202  
Parabrachial nucleus (PB), apnea arousal circuitry, 63–68  
Parkinson's disease (PD)  
deep brain stimulation, 264–267  
electrochemical detection of neurotransmitters in striatum during active investment game, 76–79  
honeybee neurons, 230  
Parvalbumin (PV) interneuron  
plasticity  
delayed onset, 28–29  
neuron subpopulations in implementation, 27–28  
overview, 25  
persistence, 28–29  
prospects for study, 32–33  
provisional and definite reinforced learning, 25–27  
time windows  
acquisition for consolidation, 29–30  
plasticity-dependent consolidation, 30–32  
research applications, 3  
PB. *See* Parabrachial nucleus  
PD. *See* Parkinson's disease  
PFC. *See* Prefrontal cortex  
Pick's disease, tau conformers, 167–169  
Plasticity  
nucleus accumbens and drug addiction changes, 132–133  
parvalbumin interneuron plasticity  
delayed onset, 28–29

- neuron subpopulations in
    - implementation, 27–28
  - overview, 25
  - persistence, 28–29
  - prospects for study, 32–33
  - provisional and definite reinforced learning, 25–27
  - time windows
    - acquisition for consolidation, 29–30
    - plasticity-dependent consolidation, 30–32
  - synaptic plasticity mechanisms, 261–262
  - transcranial magnetic stimulation
    - neuroplasticity mechanisms, 174–175
  - Polygenic risk score (PRS), 21
  - Postsynaptic proteome. *See* Synaptic theory
  - Posttraumatic stress disorder (PTSD), diagnosis, 1
  - Prefrontal cortex (PFC)
    - adolescence studies
      - axonal bouton changes, 40–41
      - dendritic spine dynamics in puberty, 39
      - inhibitory neurotransmission onto pyramidal neurons, 39–40
    - dendritic spine maturation, 37–38
    - transcranial magnetic stimulation
      - effects in addiction, 173, 175–176
  - Prion disease, 253–254
  - PRS. *See* Polygenic risk score
  - PSD95, 46–48
  - PSEN1/2*. *See* Alzheimer's disease, 152
  - PTSD. *See* Posttraumatic stress disorder
  - PV interneuron. *See* Parvalbumin interneuron
- Q**
- Q-learning, 232
  - QTL. *See* Quantitative trait loci
  - Quantitative trait loci (QTL), psychiatric disease mechanism
    - identification, 20–21
- R**
- Rett syndrome, 295
  - Reward prediction error
    - dopamine signaling, 83–84
    - hypothesis testing with electrochemical detection of brain neurotransmitters, 80–81
- S**
- SAD. *See* Social anxiety disorder
  - SAP102, 46
  - SARM1
    - discovery, 210
    - function, 210–211
    - neuroprotection, 211
    - structure, 210–211
  - Schizophrenia
    - developmental trajectory of molecular pathways, 19–20
    - hippocampal abnormalities, 108–109
    - social dysfunction, 108–109
    - social mapping impairment, 109
  - SCN1A. *See* Dravet syndrome
  - Selective serotonin reuptake inhibitors (SSRIs), 230, 264
  - Serotonin. *See also* Electrochemical detection,
    - neurotransmitters;
      - Nucleus accumbens
    - measurement in brain, 233–234
    - transporter binding by Ecstasy, 263
  - Sleep
    - Drosophila* models
      - advantages, 57–58
      - forward genetic screens of sleep mutants, 58
    - nemuri*
      - antimicrobial peptide product, 59
      - overexpression and sleep induction, 58–59
      - sleep deprivation induction, 59–60
    - drug development, 244
    - REM sleep, 243
  - SMN1*, 293
  - SMN2*, 293
  - Social anxiety disorder (SAD)
    - hippocampal abnormalities, 112
    - social dysfunction, 111–112
    - social mapping impairment, 112
  - Social isolation stress
    - brain changes in mice after prolonged isolation, 100
    - corticotropin-releasing hormone role, 101
    - neuropeptide mediation of internal state, 97–98
  - tachykinin control
    - Drosophila*, 98–99
    - mice, 99–100
    - other stress responses, 101
    - prospects for study, 101–102
    - Tac2 role, 100–101
  - SORL1, 196, 278
  - SSRIs. *See* Selective serotonin reuptake inhibitors
  - Stress. *See* Social isolation stress
  - Striatum
    - compartmentalization based on dopamine signals, 91–93
    - deep brain stimulation in Alzheimer's disease, 203–204
    - electrochemical detection of neurotransmitters during active investment game, 76–79
  - learning from different outcomes
    - algorithm, 90
- Substance abuse**
- brain reward region corruption, 131–132, 262
  - chromatin regulation, 135–136
  - neuroplastic changes, 287
  - nucleus accumbens and addiction
    - gene expression long-lasting changes, 133–134
    - medium spiny neurons expressing D1 and D2 receptors, 137–138
    - plasticity changes, 132–133
  - transcranial magnetic stimulation for addiction
    - clinical studies, 176–181
    - neurobiology, 174–175
    - overview, 173–174
    - preclinical studies, 175–176
    - prospects, 176, 182
    - transcriptional priming, 131
- Synaptic theory, behavior**
- defining features, 49
  - evolution of theory, 53
  - learning and long-term potentiation, 51–52
  - map response to patterns of activity, 49–51
  - mapping
    - complex responses, 53–54
    - synapse diversity, 46–47
  - mutation and disease, 52–53
  - overview, 45
  - postsynaptic proteome
    - innate and learned behavior control, 48
    - molecular complexity, 46
    - organization, 46
    - origins, 48–49
    - prospects, 54
    - repertoire of behaviors, 52
    - timescales and synaptic strength, 47
- SYNGAP1*, 222
- T**
- Tachykinin
    - social isolation stress control
      - Drosophila*, 98–99
      - mice, 99–100
      - prospects for study, 101–102
      - Tac2 role, 100–101
    - stress response roles, 101
  - Tau. *See also* Alzheimer's disease
  - Conformers
    - Alzheimer's disease, 166–167
    - Pick's disease, 167–169
  - filament assembly, 165
  - isoforms, 164–165
  - MAPT* genetics, 165–166
  - structure, 163–164
- TMS. *See* Transcranial magnetic stimulation**

- Transcranial magnetic stimulation (TMS)  
addiction studies  
  clinical studies, 176–181  
  overview, 173–174  
  preclinical studies, 175–176  
  prospects, 176, 182  
  applications, 222
- Dravet syndrome, 185  
neuroplasticity mechanisms, 174–175  
repetitive, 5
- V
- Ventrolateral medulla (VLM), apnea arousal  
  circuitry, 63–64, 66
- VLM. *See* Ventrolateral medulla  
*VPS35*, 196
- W**
- Wallerian degeneration  
  P7C3 protection, 212  
  slow mice, 207–210